A retrospective cohort study evaluating postoperative pain management strategies in patients undergoing gynecologic surgery has found that the common practice of adding butorphanol to sufentanil-based multimodal intravenous patient-controlled analgesia (PCA) does not yield significant improvements in early pain relief. Instead, this adjunctive treatment is associated with a markedly higher incidence of adverse neurological and gastrointestinal symptoms, particularly dizziness and nausea. The study, conducted at the First Affiliated Hospital of Wenzhou Medical University between July 2022 and June 2025, analyzed 1557 treatment records to investigate whether adding butorphanol—a mixed opioid agonist–antagonist—provides an incremental clinical benefit compared to established sufentanil-based regimens. The findings suggest that the clinical burden of additional adverse effects outweighs any detectable improvement in analgesic control during the critical first postoperative day, providing evidence that may influence prescribing patterns for patients at high risk for nausea and dizziness.
Patients undergoing gynecologic surgery represent a cohort with a particularly high susceptibility to postoperative nausea and vomiting, driven by factors such as general anesthesia, hormonal fluctuations, and pelvic organ manipulation. Intravenous PCA is frequently employed as the standard for managing acute postoperative pain, allowing patients to self-administer analgesics. However, selecting an appropriate PCA regimen necessitates a careful balance between achieving effective pain suppression and minimizing treatment-emergent adverse symptoms. While butorphanol—which primarily acts as a kappa-opioid receptor agonist and partial agonist or antagonist at mu-opioid receptors—is frequently integrated into various PCA formulations, the evidence supporting its use as an add-on to existing sufentanil-based therapy has remained limited. The researchers aimed to address this uncertainty by conducting a rigorous comparative evaluation of pain intensity and patient safety outcomes.
The study was designed as a single-center retrospective analysis, utilizing data from a larger surgical database encompassing nearly 240,000 surgical records generated during the three-year study period. Following a systematic selection process, the final analysis included 1557 treatment records, categorized into a butorphanol-exposed group of 239 records and a control group of 1318 records. To ensure robust comparisons and account for potential biases inherent in retrospective prescribing patterns—where clinicians might selectively assign butorphanol to patients with anticipated higher pain levels—the researchers employed propensity score overlap weighting. This statistical method allowed for the balancing of various demographic and clinical characteristics between the two groups, including body mass index, ASA physical status, surgical approach, and baseline PCA pump settings, effectively reducing the influence of extreme treatment probabilities and ensuring that the compared populations were clinically comparable.
Regarding the primary effectiveness outcome, the study utilized the numeric rating scale (NRS) to assess movement-evoked pain intensity on the first postoperative day. The results revealed no statistically significant differences in pain control between the two groups. After overlap weighting, the adjusted mean movement-evoked pain NRS was 1.63 in the butorphanol-containing group compared to 1.62 in the control group, representing a negligible adjusted mean difference of 0.01 points. Similarly, no clear between-group differences were identified in resting pain scores or the total volume of PCA medication delivered during the observation period. These results imply that the addition of butorphanol to the standardized base regimen of sufentanil did not materially enhance the analgesic effectiveness during the early postoperative phase for this specific surgical population.
The safety assessment, however, painted a different picture, highlighting clear disparities in adverse symptom frequency. Any postoperative dizziness occurred in 13.6% of the records involving butorphanol, compared to 6.0% in the control group. The adjusted risk difference was 7.7 percentage points, with an odds ratio of 2.49, indicating a more than twofold increase in the likelihood of dizziness associated with the addition of butorphanol. Furthermore, moderate-to-severe dizziness was also significantly more frequent in the exposed group. These findings were supported by increased rates of nausea, which affected 24.3% of the butorphanol-exposed records versus 15.4% of the controls, and a notable surge in the co-occurrence of both dizziness and nausea, which was observed in 9.5% of butorphanol-containing regimens compared to 1.8% of controls.
The study also explored potential resource-use implications by analyzing hospital billing and service data. While median hospital length of stay and total hospitalization charges did not differ between the treatment groups, anesthesia-related charges were significantly higher for patients who received butorphanol. Specifically, the analysis identified elevated costs associated with anesthetic agents and disposable medical consumables, resulting in an adjusted mean difference of 515 Chinese Yuan. Although the researchers explicitly noted that this exploratory resource-use analysis did not constitute a formal cost-effectiveness evaluation and that the results might be confounded by clinician decisions based on patient complexity, the findings consistently placed the adjunctive butorphanol strategy in a quadrant characterized by both higher costs and a higher risk of adverse symptoms compared to the control regimen.
To confirm the validity of their findings, the research team conducted several sensitivity analyses, including restricting the analysis to a predominant 2-mg butorphanol dosage and employing propensity score matching at various ratios (1:1, 1:2, 1:4). These analyses maintained consistency with the primary results, demonstrating that the observed association between butorphanol and increased dizziness was robust across different methodological approaches. A post hoc dose–response analysis was also performed, though it failed to establish a clear, monotonic relationship between the prescribed butorphanol dose and adverse events once outlier high-dose prescriptions were excluded, suggesting that the clinical impact on dizziness might not be strictly predictable solely by the starting reservoir dose.
The researchers suggested that several pharmacological mechanisms could explain why adding butorphanol contributes to adverse effects without providing proportional analgesic gains. Both sufentanil and butorphanol can influence the chemoreceptor trigger zone and the area postrema in the brainstem, which are critical areas for emetic signaling. Furthermore, the kappa-opioid receptor agonist activity of butorphanol is well-recognized for causing centrally mediated dizziness, sedation, and gastrointestinal discomfort. When combined with a highly selective mu-opioid receptor agonist like sufentanil, the overlapping mechanisms may overwhelm the patient’s neurological and vestibular systems, resulting in side effects that impede recovery goals such as early mobilization and the ability to tolerate oral intake.
This study is subject to several inherent limitations, including its retrospective, single-center design, which necessitates interpreting the results as associations rather than definitive causal evidence. The reliance on routine institutional follow-up documentation rather than standardized patient-reported outcome measures could also contribute to potential underreporting of symptoms. Moreover, follow-up was limited to the first postoperative day, and the prescribed reservoir dose did not directly correlate with the actual cumulative delivered drug exposure. These factors underscore the need for prospective, randomized, and controlled clinical trials that incorporate standardized dosing protocols, long-term follow-up, and validated assessment tools to refine the understanding of how butorphanol impacts the benefit–risk balance in multimodal analgesia.
Ultimately, these findings provide real-world evidence suggesting that the routine addition of butorphanol to sufentanil-containing PCA regimens in gynecologic surgery does not enhance early postoperative pain management. For clinicians, the data emphasize that the increased likelihood of dizziness and nausea may create an unfavorable symptom burden that interferes with patient recovery. The authors conclude that if clinicians believe the inclusion of butorphanol is required for specific patient pain profiles, it should be accompanied by enhanced monitoring for neurologic and gastrointestinal distress, particularly among patients who are known to be highly susceptible to opioid-induced adverse symptoms. This analysis highlights the importance of critically evaluating established clinical practices to ensure that therapeutic additions truly provide meaningful benefits to patients.
Subject of Research: Clinical pharmacology and postoperative pain management outcomes
Article Title: Safety and Analgesic Effectiveness of Adding Butorphanol to Multimodal Intravenous Patient-Controlled Analgesia After Gynecologic Surgery: A Retrospective Cohort Study
Article References: Ye, Y., Feng, C., Dong, Y., Wu, F., Gong, H., Wu, Y., & Xia, F. (2026). Safety and Analgesic Effectiveness of Adding Butorphanol to Multimodal Intravenous Patient-Controlled Analgesia After Gynecologic Surgery: A Retrospective Cohort Study. Pain and Therapy, 15(6), 1859-1880. https://doi.org/10.1007/s40122-026-00897-w
Image Credits: AI Generated
DOI: 10.1007/s40122-026-00897-w
Keywords: gynecologic surgery, patient-controlled analgesia, butorphanol, sufentanil, postoperative pain, nausea, dizziness, opioid pharmacology, clinical research, pain management, anesthesia, retrospective cohort, drug safety, health economics, postoperative recovery, multimodal analgesia, adverse symptoms, real-world evidence
News Source: Ophelia Keating. (November 17, 2026). Adding Butorphanol to Post-Surgery PCA Increases Dizziness Without Improving Pain Control. Scienmag.



